Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Two-year effect and safety of once-weekly semaglutide 2.4 mg in adults with overweight or obesity
2017-003726-32Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2018
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obesity and Overweight comparing Semaglutide with Placebo (2 arms). Primary endpoint: Primary efficacy endpoint. Started Jun 2018; status: completed.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on 2017-003726-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003726-32.